Leading the Peptide Pipeline: Aoxiang Pharmaceutical Deeply Engages in Discussions on Reaction Safety Risk Assessment, Jointly Mapping Out the Industry’s Blueprint

Release Date:

2026-01-13

In recent years, Aoxiang Pharmaceutical has, while maintaining its core strengths in active pharmaceutical ingredients, steadfastly implemented a “transformation and upgrading” strategy, prioritizing the research and development of peptide drugs, oligonucleotides, and synthetic biology technologies.

Leading the Peptide Pipeline: Aoxiang Pharmaceutical Deeply Engages in Discussions on Reaction Safety Risk Assessment, Jointly Mapping Out the Industry’s Blueprint

As the global biopharmaceutical industry moves toward “ Medium molecule ” As the field accelerates its advancement, peptide drugs are emerging as the shining star of next-generation drug development, thanks to their high potency and low toxicity. Recently, a symposium on the assessment of reaction safety risks for peptide products was successfully held, organized by the Linhai City Association for the Safety of Hazardous Chemicals. As a leader in Linhai’s pharmaceutical industry and a pioneer in the peptide sector, Zhejiang Aoxiang Pharmaceutical Co., Ltd. dispatched a dedicated technical team to participate in depth, engaging in constructive dialogue with regulatory authorities and industry experts on how to strike a balance between safety and innovation.

Strategic Focus: Aoxiang Pharmaceutical’s Peptides “ Ambition ”

In recent years, Aoxiang Pharmaceutical has, while maintaining its core strengths in active pharmaceutical ingredients, steadfastly implemented “ Transformation and upgrading ” The strategy prioritizes peptide drugs, oligonucleotides, and synthetic biology as the core areas of R&D innovation.

Currently, Aoxiang Pharmaceutical has proactively positioned itself in the peptide field, with several pipeline products covering key therapeutic areas such as metabolic diseases and cardiovascular and cerebrovascular disorders. Leveraging its existing strengths in chiral synthesis technology and an internationally aligned quality system, the company has successfully overcome the highly challenging technical barriers in the synthesis of long-peptide chains. Participation in this symposium not only underscores Aoxiang’s unwavering commitment to safe production but also sends a strong signal: Aoxiang Pharmaceutical’s peptide business has entered a phase of accelerated development and is advancing through the establishment of “ Research and Development - Safety - Production capacity ” A full-dimensional value chain, striving to capture the global high-end peptide market.

Policy Support: Linhai City’s “ Flexible Regulation ” Temperature

Behind this conference lies the high level of attention and targeted support that the relevant departments of Linhai City have accorded to peptides as a strategic emerging industry.

From “ Strict regulation ” to “ Precise assessment ”： The Linhai Municipal Emergency Management Bureau and the Safety Association, recognizing the pain points of numerous peptide synthesis steps and complex evaluation processes, took the lead in developing streamlined, scientifically sound assessment guidelines, thereby significantly reducing R&D costs and time-to-market for innovative companies such as Aoxiang Pharmaceutical.
Building an Industrial Hub: This kind of “ Government provides the platform, associations take the lead, and enterprises participate. ” This model reflects Linhai City’s determination to elevate and differentiate its local pharmaceutical industry, with the aim of establishing a leading position in the niche segment of peptide drugs. “ Linhai Model ”。

Expert Perspective: The Value of Optimizing Security Assessment Solutions

The “Discussion Recommendations on the Safety Risk Assessment of Reactions Involving Peptide Products in Linhai City” formulated at the seminar is regarded within the industry as a guideline for corporate R&D. “ Order to Reduce Burden ”。

“ This optimization plan, developed with the participation of companies such as Aoxiang Pharmaceutical, is based on the common bond-energy characteristics of peptide synthesis to conduct scientifically informed sampling, thereby upholding the safety baseline while significantly boosting productivity. ” The experts in attendance stated.

Looking Ahead: Innovation-Driven, Safety-Led

A representative from Aoxiang Pharmaceutical stated: “ Peptide products represent a key growth driver for Aoxiang’s future. The relevant authorities in Linhai City have optimized the risk-assessment process, effectively resolving bottlenecks in our project implementation and bolstering our confidence to increase investment. ”

As Aoxiang Pharmaceutical continues to deepen its expertise in the peptide field, coupled with Linhai City’s increasingly comprehensive supporting infrastructure and technical standards, a platform that integrates “ Green synthesis, safety and efficiency, technological innovation ” A multi-peptide industry cluster integrating [various elements] is rapidly emerging along the coast of the East China Sea. Aoxiang Pharmaceutical will continue to uphold “ Quality and Innovation ” the vision of providing more high-quality peptide drugs to patients worldwide, contributing “ China's Innovation ” the power of.